Complete financial analysis of Sol-Gel Technologies Ltd. (SLGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sol-Gel Technologies Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Crowell Development Corp. (2528.TW) Income Statement Analysis – Financial Results
- PJSC Tatneft (OAOFY) Income Statement Analysis – Financial Results
- Gokul Agro Resources Limited (GOKULAGRO.NS) Income Statement Analysis – Financial Results
- Group Eleven Resources Corp. (GRLVF) Income Statement Analysis – Financial Results
- Sirius Real Estate Limited (SRRLF) Income Statement Analysis – Financial Results
Sol-Gel Technologies Ltd. (SLGL)
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.55M | 3.88M | 31.27M | 8.77M | 22.90M | 129.00K | 174.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 300.00K | 359.00K | 300.00K | 0.00 |
| Gross Profit | -21.99M | -8.80M | 10.89M | -19.14M | -17.67M | -28.02M | -126.00K | -359.00K | -300.00K | 0.00 |
| Gross Profit Ratio | -1,414.86% | -226.60% | 34.83% | -218.24% | -77.17% | -21,718.60% | -72.41% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 25.81M | 17.02M | 7.18M | 2.93M |
| General & Administrative | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Other Expenses | -55.00K | 0.00 | -524.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Cost & Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Interest Income | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 40.00K |
| Interest Expense | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 342.00K | 562.00K | 880.00K | 946.00K | 887.00K | 762.00K | 300.00K | 359.00K | 300.00K | 225.00K |
| EBITDA | -28.96M | -15.68M | 3.84M | -29.29M | -25.06M | -32.76M | -31.16M | -20.40M | -9.35M | -4.58M |
| EBITDA Ratio | -1,863.77% | -403.86% | 9.48% | -344.69% | -109.43% | -25,394.57% | -17,909.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.31M | -16.24M | 2.08M | -30.23M | 25.95M | -33.52M | -31.63M | -20.76M | -9.65M | -4.81M |
| Operating Income Ratio | -1,885.78% | -418.34% | 6.66% | -344.69% | 113.30% | -25,985.27% | -18,179.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 1.32M | 65.00K | -15.00K | -13.00K | -40.00K |
| Income Before Tax | -27.24M | -14.92M | 3.22M | -29.29M | -24.58M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Income Before Tax Ratio | -1,752.77% | -384.32% | 10.30% | -333.94% | -107.30% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -1.14M | -1.89M | 33.00K | -1.32M | -65.00K | 15.00K | 13.00K | 0.00 |
| Net Income | -27.24M | -13.60M | 4.36M | -27.40M | -24.61M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Net Income Ratio | -1,752.77% | -350.30% | 13.94% | -312.40% | -107.44% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -0.59 | 0.19 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| EPS Diluted | -1.01 | -0.59 | 0.18 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| Weighted Avg Shares Out | 27.09M | 23.13M | 23.06M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
| Weighted Avg Shares Out (Dil) | 27.09M | 23.13M | 23.57M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
Earnings Preview: SolGel Technologies Ltd. (SLGL) Q1 Earnings Expected to Decline
SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company...
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company...
SolGel Technologies Ltd. (SLGL) Reports Q2 Loss, Misses Revenue Estimates
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -75.00% and -71.55%, respectively, for the quarter ended June 2021.
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
NESS ZIONA, Israel, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the...
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older. Twyneo uses Sol-Gel's patented technology to entrap tretinoin, a retinoid,...
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
NESS ZIONA, Israel, July 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Food and Drug...
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter...
Sol-Gel Announces Pipeline Update and Future Development Plans
NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre-clinical...
Source: https://incomestatements.info
Category: Stock Reports